<p>藥明康德（NASDAQ:BEAM - 獲取免費報告）在週五發佈給客户和投資者的研究報告中，被美國銀行從 “中性” 評級上調至 “買入” 評級，Briefing.com 自動導入報告稱。該券商目前對該股票的目標價為 42.00 美元。美國銀行的目標價表明，與公司當前價格相比，潛在上漲幅度為 89.27%。</p>
<p>獲取 <strong>Beam Therapeutics</strong> 警報：</p>
<ul>
<li>MarketBeat 週迴顧 – 3/4 – 3/8</li>
</ul>
<p>其他一些股票研究分析師也對該股票發表了看法。加拿大皇家銀行將藥明康德的目標價從 24.00 美元上調至 26.00 美元，並在 2 月 26 日的研究報告中給予該公司 “行業表現” 評級。古根海姆在 2 月 27 日的報告中重申了 “買入” 評級，並對藥明康德的股票發佈了 78.00 美元的目標價。Wedbush 在 3 月 10 日的報告中重申了 “跑贏大盤” 評級，並設定了 57.00 美元的目標價。加拿大豐業銀行在 3 月 10 日的報告中將藥明康德的評級從 “行業表現” 上調至 “行業跑贏大盤”，並設定了 40.00 美元的目標價。最後，Cantor Fitzgerald 在 3 月 12 日的研究報告中重申了對藥明康德股票的 “增持” 評級。兩位分析師對該股票給予了持有評級，十位分析師給予了買入評級，另外兩位分析師給予了強烈買入評級。根據 MarketBeat.com 的數據，該股票目前的共識評級為 “買入”，共識目標價為 49.45 美元。</p>
<p><strong>獲取我們最新的 BEAM 股票分析</strong></p>
<h2>Beam Therapeutics 股票上漲 1.3%</h2>
<ul>
<li>Beam Therapeutics 因基因治療許可付款而大幅上漲</li>
</ul>
<p>NASDAQ:BEAM 週五開盤價為 22.19 美元。該股票的市值為 22.1 億美元，市盈率為-12.61，貝塔值為 1.91。該公司的 50 日移動平均線為 26.67 美元，200 日移動平均線為 25.87 美元。藥明康德的 12 個月低點為 20.84 美元，12 個月高點為 35.25 美元。</p>
<p>藥明康德（NASDAQ:BEAM - 獲取免費報告）最近一次發佈財報是在 2 月 25 日。該公司報告本季度每股收益為（1.09 美元），超出市場共識預期的（1.25 美元）0.16 美元。該季度的營業收入為 3000 萬美元，而市場共識預期為 1647 萬美元。藥明康德的股本回報率為-16.22%，淨利潤率為-41.07%。該公司的收入與去年同期相比下降了 90.5%。去年同期，該公司每股收益為 1.73 美元。研究分析師預測，藥明康德在本年度的每股收益將為-4.57 美元。</p>
<h2>Beam Therapeutics 內部活動</h2>
<ul>
<li>CRISPR Therapeutics 是基因編輯領域的 NVIDIA 嗎？</li>
</ul>
<p>在其他新聞中，首席執行官 John M. Evans 於 1 月 30 日出售了 30,000 股藥明康德股票，交易價格為 26.75 美元，總價值為 802,500.00 美元。出售後，首席執行官現在持有 908,659 股公司股票，價值為 24,306,628.25 美元。此次交易使其持股比例減少了 3.20%。該交易在向證券交易委員會的法律文件中披露，相關文件可通過此鏈接訪問。此外，內部人士 Christine Bellon 於 1 月 2 日出售了 1,241 股藥明康德股票，交易價格為 24.68 美元，總價值為 30,627.88 美元。出售完成後，該內部人士現在持有 102,968 股公司股票，價值約為 2,541,250.24 美元。此次交易使其持股比例減少了 1.19%。該交易的披露信息可以在此找到。內部人士持有公司股票的 4.20%。</p>
<h2>機構資金流入和流出</h2>
<p>機構投資者最近增加或減少了對公司的持股。Wealthfront Advisers LLC 在第四季度購買了價值 41,000 美元的藥明康德新股份。GF Fund Management CO. LTD. 在第四季度購買了價值 43,000 美元的藥明康德新股份。Sterling Capital Management LLC 在第四季度將其在藥明康德的持股增加了 816.0%。Sterling Capital Management LLC 現在持有 2,409 股公司股票，價值 60,000 美元，此前在該期間內又購買了 2,146 股。KBC Group NV 在第四季度將其在藥明康德的持股增加了 103.2%。KBC Group NV 現在持有 4,143 股公司股票，價值 103,000 美元，此前在上個季度又購買了 2,104 股。最後，Blue Trust Inc. 在第四季度將其在藥明康德的持股增加了 36.3%。Blue Trust Inc. 現在持有 4,274 股公司股票，價值 105,000 美元，此前在該期間內又購買了 1,139 股。機構投資者和對沖基金持有公司 99.68% 的股票。</p>
<h2>Beam Therapeutics 公司簡介</h2>
<p>（獲取免費報告）</p>
<p>藥明康德是一家生物技術公司，專注於為美國患有嚴重疾病的患者開發精準基因藥物。它開發了用於治療鐮狀細胞病或β-地中海貧血的 BEAM-101；用於治療嚴重的α-1 抗胰蛋白酶缺乏症的肝臟靶向 LNP 製劑 BEAM-302；用於治療難治性 T 細胞急性淋巴細胞白血病/T 細胞淋巴母細胞瘤的抗 CD7 CAR-T 產品候選藥物 BEAM-201，目前處於 1/2 期臨牀試驗階段；以及用於治療糖原貯積病 1a 的肝臟靶向 LNP 製劑 BEAM-301。</p>
<h2>進一步閲讀</h2>
<ul>
<li>我們更看好的五隻股票，而不是 Beam Therapeutics</li>
<li>優先股與普通股的投資</li>
<li>3 只接近 52 周高點的動量股，值得關注以獲取更多增長</li>
<li>商業服務股票投資</li>
<li>微軟在馬來西亞的大賭注可能會為投資者帶來回報</li>
<li>一些最佳的大盤股有哪些？</li>
<li>市場上被嚴重超賣的五隻股票是…</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsAndPriceTargetChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9QkVBTQ?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsAndPriceTargetChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9QkVBTQ"/></p>
<p><em>此即時新聞提醒由敍事科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快和最準確的報道。此故事在發佈前已由 MarketBeat 的編輯團隊審核。請將任何問題或意見發送至 contact@marketbeat.com.</em></p>
<h2>你現在應該投資 1,000 美元在 Beam Therapeutics 嗎？</h2>
<p>在考慮 Beam Therapeutics 之前，你需要聽聽這個。</p>
<p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦給客户的股票。MarketBeat 已識別出五隻頂級分析師悄悄向客户推薦的股票，建議在更廣泛的市場注意到之前購買……而 Beam Therapeutics 並不在名單上。</p>
<p>雖然 Beam Therapeutics 目前在分析師中獲得了買入評級，但頂級分析師認為這五隻股票更值得購買。</p>
<p>在這裏查看這五隻股票</p>

BEAM

<p>美國銀行將 Beam Therapeutics（納斯達克代碼：BEAM）的評級從 “中性” 上調至 “買入”，設定目標價格為 42.00 美元，暗示潛在上漲空間為 89.27%。其他分析師也提高了他們的目標價格，普遍評級為 “買入”，平均目標為 49.45 美元。Beam Therapeutics 報告的季度每股收益為（1.09 美元），超出預期，收入為 3000 萬美元。該股開盤價為 22.19 美元，市值為 22.1 億美元。內部交易活動包括首席執行官 John M. Evans 出售了 30,000 股</p>

<p>Beam Therapeutics (NASDAQ:BEAM - Get Free Report) was upgraded by Bank of America from a &#34;neutral&#34; rating to a &#34;buy&#34; rating in a research report issued to clients and investors on Friday,Briefing.com Automated Import reports. The brokerage presently has a $42.00 price objective on the stock. Bank of America's price target indicates a potential upside of 89.27% from the company's current price.</p>
<div class="lb-trans"><p>藥明康德（NASDAQ:BEAM - 獲取免費報告）在週五發佈給客户和投資者的研究報告中，被美國銀行從 “中性” 評級上調至 “買入” 評級，Briefing.com 自動導入報告稱。該券商目前對該股票的目標價為 42.00 美元。美國銀行的目標價表明，與公司當前價格相比，潛在上漲幅度為 89.27%。</p>
</div><p>Get <strong>Beam Therapeutics</strong> alerts:</p>
<div class="lb-trans"><p>獲取 <strong>Beam Therapeutics</strong> 警報：</p>
</div><ul>
<li>MarketBeat Week in Review – 3/4 – 3/8</li>
</ul>
<div class="lb-trans"><ul>
<li>MarketBeat 週迴顧 – 3/4 – 3/8</li>
</ul>
</div><p>A number of other equities research analysts have also weighed in on the stock. Royal Bank of Canada lifted their target price on shares of Beam Therapeutics from $24.00 to $26.00 and gave the company a &#34;sector perform&#34; rating in a research note on Wednesday, February 26th. Guggenheim restated a &#34;buy&#34; rating and issued a $78.00 price objective on shares of Beam Therapeutics in a report on Thursday, February 27th. Wedbush reaffirmed an &#34;outperform&#34; rating and set a $57.00 price target on shares of Beam Therapeutics in a report on Monday, March 10th. Scotiabank raised Beam Therapeutics from a &#34;sector perform&#34; rating to a &#34;sector outperform&#34; rating and set a $40.00 target price on the stock in a report on Monday, March 10th. Finally, Cantor Fitzgerald restated an &#34;overweight&#34; rating on shares of Beam Therapeutics in a research note on Wednesday, March 12th. Two analysts have rated the stock with a hold rating, ten have given a buy rating and two have issued a strong buy rating to the stock. According to MarketBeat.com, the stock currently has a consensus rating of &#34;Buy&#34; and a consensus target price of $49.45.</p>
<div class="lb-trans"><p>其他一些股票研究分析師也對該股票發表了看法。加拿大皇家銀行將藥明康德的目標價從 24.00 美元上調至 26.00 美元，並在 2 月 26 日的研究報告中給予該公司 “行業表現” 評級。古根海姆在 2 月 27 日的報告中重申了 “買入” 評級，並對藥明康德的股票發佈了 78.00 美元的目標價。Wedbush 在 3 月 10 日的報告中重申了 “跑贏大盤” 評級，並設定了 57.00 美元的目標價。加拿大豐業銀行在 3 月 10 日的報告中將藥明康德的評級從 “行業表現” 上調至 “行業跑贏大盤”，並設定了 40.00 美元的目標價。最後，Cantor Fitzgerald 在 3 月 12 日的研究報告中重申了對藥明康德股票的 “增持” 評級。兩位分析師對該股票給予了持有評級，十位分析師給予了買入評級，另外兩位分析師給予了強烈買入評級。根據 MarketBeat.com 的數據，該股票目前的共識評級為 “買入”，共識目標價為 49.45 美元。</p>
</div><p><strong>Get Our Latest Stock Analysis on BEAM</strong></p>
<div class="lb-trans"><p><strong>獲取我們最新的 BEAM 股票分析</strong></p>
</div><h2>Beam Therapeutics Trading Up 1.3 %</h2>
<div class="lb-trans"><h2>Beam Therapeutics 股票上漲 1.3%</h2>
</div><ul>
<li>Beam Therapeutics Bolts Higher on Gene Therapy Licensing Payments</li>
</ul>
<div class="lb-trans"><ul>
<li>Beam Therapeutics 因基因治療許可付款而大幅上漲</li>
</ul>
</div><p>NASDAQ:BEAM opened at $22.19 on Friday. The stock has a market capitalization of $2.21 billion, a PE ratio of -12.61 and a beta of 1.91. The firm's 50 day moving average is $26.67 and its 200 day moving average is $25.87. Beam Therapeutics has a 12 month low of $20.84 and a 12 month high of $35.25.</p>
<div class="lb-trans"><p>NASDAQ:BEAM 週五開盤價為 22.19 美元。該股票的市值為 22.1 億美元，市盈率為-12.61，貝塔值為 1.91。該公司的 50 日移動平均線為 26.67 美元，200 日移動平均線為 25.87 美元。藥明康德的 12 個月低點為 20.84 美元，12 個月高點為 35.25 美元。</p>
</div><p>Beam Therapeutics (NASDAQ:BEAM - Get Free Report) last issued its earnings results on Tuesday, February 25th. The company reported ($1.09) EPS for the quarter, topping the consensus estimate of ($1.25) by $0.16. The business had revenue of $30.00 million during the quarter, compared to the consensus estimate of $16.47 million. Beam Therapeutics had a negative return on equity of 16.22% and a negative net margin of 41.07%. The firm's revenue was down 90.5% compared to the same quarter last year. During the same quarter last year, the company earned $1.73 EPS. Research analysts predict that Beam Therapeutics will post -4.57 earnings per share for the current year.</p>
<div class="lb-trans"><p>藥明康德（NASDAQ:BEAM - 獲取免費報告）最近一次發佈財報是在 2 月 25 日。該公司報告本季度每股收益為（1.09 美元），超出市場共識預期的（1.25 美元）0.16 美元。該季度的營業收入為 3000 萬美元，而市場共識預期為 1647 萬美元。藥明康德的股本回報率為-16.22%，淨利潤率為-41.07%。該公司的收入與去年同期相比下降了 90.5%。去年同期，該公司每股收益為 1.73 美元。研究分析師預測，藥明康德在本年度的每股收益將為-4.57 美元。</p>
</div><h2>Insider Activity at Beam Therapeutics</h2>
<div class="lb-trans"><h2>Beam Therapeutics 內部活動</h2>
</div><ul>
<li>Is CRISPR Therapeutics the NVIDIA of gene editing?</li>
</ul>
<div class="lb-trans"><ul>
<li>CRISPR Therapeutics 是基因編輯領域的 NVIDIA 嗎？</li>
</ul>
</div><p>In other news, CEO John M. Evans sold 30,000 shares of Beam Therapeutics stock in a transaction dated Thursday, January 30th. The shares were sold at an average price of $26.75, for a total value of $802,500.00. Following the sale, the chief executive officer now owns 908,659 shares of the company's stock, valued at $24,306,628.25. The trade was a 3.20 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities &amp; Exchange Commission, which is accessible through this hyperlink. Also, insider Christine Bellon sold 1,241 shares of Beam Therapeutics stock in a transaction that occurred on Thursday, January 2nd. The shares were sold at an average price of $24.68, for a total value of $30,627.88. Following the completion of the sale, the insider now owns 102,968 shares in the company, valued at approximately $2,541,250.24. This trade represents a 1.19 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders own 4.20% of the company's stock.</p>
<div class="lb-trans"><p>在其他新聞中，首席執行官 John M. Evans 於 1 月 30 日出售了 30,000 股藥明康德股票，交易價格為 26.75 美元，總價值為 802,500.00 美元。出售後，首席執行官現在持有 908,659 股公司股票，價值為 24,306,628.25 美元。此次交易使其持股比例減少了 3.20%。該交易在向證券交易委員會的法律文件中披露，相關文件可通過此鏈接訪問。此外，內部人士 Christine Bellon 於 1 月 2 日出售了 1,241 股藥明康德股票，交易價格為 24.68 美元，總價值為 30,627.88 美元。出售完成後，該內部人士現在持有 102,968 股公司股票，價值約為 2,541,250.24 美元。此次交易使其持股比例減少了 1.19%。該交易的披露信息可以在此找到。內部人士持有公司股票的 4.20%。</p>
</div><h2>Institutional Inflows and Outflows</h2>
<div class="lb-trans"><h2>機構資金流入和流出</h2>
</div><p>Institutional investors have recently added to or reduced their stakes in the company. Wealthfront Advisers LLC purchased a new stake in shares of Beam Therapeutics during the 4th quarter valued at $41,000. GF Fund Management CO. LTD. purchased a new position in shares of Beam Therapeutics in the 4th quarter valued at $43,000. Sterling Capital Management LLC raised its stake in shares of Beam Therapeutics by 816.0% in the 4th quarter. Sterling Capital Management LLC now owns 2,409 shares of the company's stock valued at $60,000 after acquiring an additional 2,146 shares during the period. KBC Group NV lifted its holdings in shares of Beam Therapeutics by 103.2% during the 4th quarter. KBC Group NV now owns 4,143 shares of the company's stock valued at $103,000 after acquiring an additional 2,104 shares in the last quarter. Finally, Blue Trust Inc. boosted its position in Beam Therapeutics by 36.3% during the 4th quarter. Blue Trust Inc. now owns 4,274 shares of the company's stock worth $105,000 after purchasing an additional 1,139 shares during the period. Institutional investors and hedge funds own 99.68% of the company's stock.</p>
<div class="lb-trans"><p>機構投資者最近增加或減少了對公司的持股。Wealthfront Advisers LLC 在第四季度購買了價值 41,000 美元的藥明康德新股份。GF Fund Management CO. LTD. 在第四季度購買了價值 43,000 美元的藥明康德新股份。Sterling Capital Management LLC 在第四季度將其在藥明康德的持股增加了 816.0%。Sterling Capital Management LLC 現在持有 2,409 股公司股票，價值 60,000 美元，此前在該期間內又購買了 2,146 股。KBC Group NV 在第四季度將其在藥明康德的持股增加了 103.2%。KBC Group NV 現在持有 4,143 股公司股票，價值 103,000 美元，此前在上個季度又購買了 2,104 股。最後，Blue Trust Inc. 在第四季度將其在藥明康德的持股增加了 36.3%。Blue Trust Inc. 現在持有 4,274 股公司股票，價值 105,000 美元，此前在該期間內又購買了 1,139 股。機構投資者和對沖基金持有公司 99.68% 的股票。</p>
</div><h2>Beam Therapeutics Company Profile</h2>
<div class="lb-trans"><h2>Beam Therapeutics 公司簡介</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（獲取免費報告）</p>
</div><p>Beam Therapeutics Inc, a biotechnology company, engages in the development of precision genetic medicines for patients suffering from serious diseases in the United States. It develops BEAM-101 for the treatment of sickle cell disease or beta-thalassemia; and BEAM-302, a liver-targeting LNP formulation to treat severe alpha-1 antitrypsin deficiency; BEAM-201, an anti-CD7 CAR-T product candidate, which is in Phase 1/2 clinical trials for the treatment of refractory T-cell acute lymphoblastic leukemia/T cell lymphoblastic lymphoma; and BEAM-301, a liver-targeting LNP formulation for the treatment of glycogen storage disease 1a.</p>
<div class="lb-trans"><p>藥明康德是一家生物技術公司，專注於為美國患有嚴重疾病的患者開發精準基因藥物。它開發了用於治療鐮狀細胞病或β-地中海貧血的 BEAM-101；用於治療嚴重的α-1 抗胰蛋白酶缺乏症的肝臟靶向 LNP 製劑 BEAM-302；用於治療難治性 T 細胞急性淋巴細胞白血病/T 細胞淋巴母細胞瘤的抗 CD7 CAR-T 產品候選藥物 BEAM-201，目前處於 1/2 期臨牀試驗階段；以及用於治療糖原貯積病 1a 的肝臟靶向 LNP 製劑 BEAM-301。</p>
</div><h2>Further Reading</h2>
<div class="lb-trans"><h2>進一步閲讀</h2>
</div><ul>
<li>Five stocks we like better than Beam Therapeutics</li>
<li>Investing In Preferred Stock vs. Common Stock</li>
<li>3 Momentum Stocks Near 52-Week Highs to Watch for More Growth</li>
<li>Business Services Stocks Investing</li>
<li>Microsoft’s Big Malaysia Bet Could Pay Off for Investors</li>
<li>What Are Some of the Best Large-Cap Stocks to Buy?</li>
<li>The 5 Most Oversold Stocks on the Market Are…</li>
</ul>
<div class="lb-trans"><ul>
<li>我們更看好的五隻股票，而不是 Beam Therapeutics</li>
<li>優先股與普通股的投資</li>
<li>3 只接近 52 周高點的動量股，值得關注以獲取更多增長</li>
<li>商業服務股票投資</li>
<li>微軟在馬來西亞的大賭注可能會為投資者帶來回報</li>
<li>一些最佳的大盤股有哪些？</li>
<li>市場上被嚴重超賣的五隻股票是…</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsAndPriceTargetChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9QkVBTQ" alt="" original-src="https://www.marketbeat.com/scripts/RatingsAndPriceTargetChart.ashx?Prefix=NASDAQ&amp;Symbol=BEAM"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即時新聞提醒由敍事科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快和最準確的報道。此故事在發佈前已由 MarketBeat 的編輯團隊審核。請將任何問題或意見發送至 contact@marketbeat.com.</em></p>
</div><h2>Should You Invest $1,000 in Beam Therapeutics Right Now?</h2>
<div class="lb-trans"><h2>你現在應該投資 1,000 美元在 Beam Therapeutics 嗎？</h2>
</div><p>Before you consider Beam Therapeutics, you'll want to hear this.</p>
<div class="lb-trans"><p>在考慮 Beam Therapeutics 之前，你需要聽聽這個。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Beam Therapeutics wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦給客户的股票。MarketBeat 已識別出五隻頂級分析師悄悄向客户推薦的股票，建議在更廣泛的市場注意到之前購買……而 Beam Therapeutics 並不在名單上。</p>
</div><p>While Beam Therapeutics currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>雖然 Beam Therapeutics 目前在分析師中獲得了買入評級，但頂級分析師認為這五隻股票更值得購買。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在這裏查看這五隻股票</p>
</div>

Beam Therapeutics（納斯達克股票代碼：BEAM）在美國銀行被上調至買入評級